The cabergoline-resistant prolactinoma patient: new challenges.
Molitch
Mark E
ME
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004452:Echocardiography; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D055815:Young Adult
D018491:Dopamine Agonists; D004873:Ergolines; D011954:Receptors, Dopamine; D011388:Prolactin; D000077465:Cabergoline